EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Jazz Pharmaceuticals PLC (JAZZ) had EBIT Margin of 15.09% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$3.83B |
|
$439.71M |
|
$435.58M |
|
$3.40B |
|
$3.26B |
|
$578.58M |
|
$-280.65M |
|
$297.93M |
|
$297.93M |
|
$417.84M |
|
$414.83M |
|
$414.83M |
|
$417.84M |
|
$578.58M |
|
$1.22B |
|
63.29M |
|
72.07M |
|
$6.55 |
|
$6.10 |
|
| Balance Sheet Financials | |
$3.44B |
|
$169.65M |
|
$7.96B |
|
$11.39B |
|
$1.54B |
|
$5.11B |
|
$6.12B |
|
$7.66B |
|
$3.74B |
|
$-3.43B |
|
$3.74B |
|
62.26M |
|
| Cash Flow Statement Financials | |
$1.09B |
|
$-163.06M |
|
$-305.25M |
|
$881.48M |
|
$1.51B |
|
$624.83M |
|
$226.84M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.24 |
|
-- |
|
-- |
|
0.58 |
|
1.53 |
|
88.64% |
|
15.09% |
|
|
EBIT Margin |
15.09% |
31.75% |
|
7.77% |
|
11.47% |
|
$1.07B |
|
-- |
|
-- |
|
-- |
|
0.34 |
|
0.73 |
|
5.43 |
|
67.19 |
|
11.10% |
|
-12.08% |
|
3.64% |
|
4.69% |
|
$60.03 |
|
$14.82 |
|
$15.15 |
|